## Gene Summary
PTEN (Phosphatase and Tensin Homolog) is a critical tumor suppressor gene that encodes a phosphatase protein known to oppose the PI3K/AKT signaling pathway, thus regulating cell cycle progression and preventing unchecked cell growth and proliferation. This function is chiefly important in controlling apoptosis and tumor suppression. PTEN is ubiquitously expressed in various tissues, with particularly high levels in the brain. The loss of its function through mutations or deletions has been strongly implicated in the development of numerous cancer types and is also associated with several inherited syndromes.

## Gene Drugs, Diseases, Phenotypes, and Pathways
Several significant diseases are associated with PTEN, particularly hereditary cancer syndromes like Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome, characterized by multiple noncancerous tumor-like growths and an increased risk of certain cancers. PTEN mutations are found in a broad spectrum of sporadic tumors, including but not limited to breast, prostate, thyroid, and endometrial cancers. This gene's role in the PI3K/AKT pathway links it to key cellular functions like cell growth and survival, translation, and transcription, making it pivotal in studies of cellular signaling pathways. Ongoing clinical trials are examining PTEN's role in therapeutic strategies, including use of targeted therapies that can modify or inhibit the PI3K/AKT pathway activities in cancers.

## Pharmacogenetics
In pharmacogenetics, PTEN status profoundly influences the response to several anticancer drugs. The loss of PTEN functionality can result in increased cell survival and proliferation through unregulated PI3K/AKT signaling, affecting the efficacy of PI3K/AKT/mTOR pathway inhibitors. For example, tumors that have PTEN deletions or mutations typically show resistance to mTOR inhibitors like everolimus and temsirolimus, which are used in treating cancers such as renal cell carcinoma and breast cancer. Moreover, understanding the PTEN mutation status can aid in the choice of using conventional chemotherapeutic agents versus targeted therapies, potentially leading to more personalized and effective treatment regimens for cancer patients.